Please login to the form below
Helsinn
This page shows the latest Helsinn news and features for those working in and with pharma, biotech and healthcare.
Fishawack acquires brand communications agency Healthcircle
The group is a network of medical communications and marketing organisation companies and has a portfolio of pharma and healthcare clients including Roche, Swiss pharma group Helsinn and phytomedicines company Schwabe
Latest news
-
Danish biopharma company wins R&D award
Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn
-
FDA approves PONV injection
Developed by Eisai Corporation of North America, its US subsidiary MGI Pharma, and Helsinn Healthcare SA (based in Switzerland), Aloxi has been shown to reduce the severity of PONV. ... Riccardo Braglia, CEO of Helsinn Healthcare SA, said: ìThis is an
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
Late stage licences can also command relatively low upfront fees. For example, Helsinn has licensed pracinostat, which is phase III-ready, for $15m upfront plus $5m equity payment. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Azafaros expands executive team with three senior hires
He joins from Helsinn Group, where he held the position of global head of clinical research and development.
-
New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics
He started his career with Eurand in Italy, and since 2011 he has worked for Helsinn Healthcare, a cancer care company.
-
Helsinn Therapeutics names Paul Rittman as CEO
I am sure his expertise, experience and network will prove invaluable in this key commercial moment for the Helsinn Group.”. ... Helsinn is an international pharmaceutical business strongly committed to growth through investing in oncology while
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
